Healthcare provider profile · identity verified

Barnali Gupta, M.D.

Internal Medicine · RENO, NV · NPI 1881698421

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	615	221
Levothyroxine Sodium	Levothyroxine Sodium	476	134
Losartan Potassium	Losartan Potassium	413	144
Amlodipine Besylate	Amlodipine Besylate	390	138
Lisinopril	Lisinopril	295	107
Albuterol Sulfate Hfa	Albuterol Sulfate	225	114
Hydrochlorothiazide	Hydrochlorothiazide	217	78
Gabapentin	Gabapentin	190	72
Trazodone Hcl	Trazodone Hcl	185	60
Metoprolol Tartrate	Metoprolol Tartrate	183	71
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	182	54
Pantoprazole Sodium	Pantoprazole Sodium	165	62
Furosemide	Furosemide	155	55
Metformin Hcl Er	Metformin Hcl	145	47
Metoprolol Succinate	Metoprolol Succinate	143	49
Duloxetine Hcl	Duloxetine Hcl	133	49
Ibuprofen	Ibuprofen	125	50
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	124	47
Atenolol	Atenolol	123	49
Fluticasone Propionate	Fluticasone Propionate	122	36
Omeprazole	Omeprazole	116	41
Famotidine	Famotidine	106	42
Simvastatin	Simvastatin	105	35
Alvesco	Ciclesonide	102	46
Tamsulosin Hcl	Tamsulosin Hcl	97	33
Sertraline Hcl	Sertraline Hcl	92	34
Alendronate Sodium	Alendronate Sodium	89	35
Potassium Chloride	Potassium Chloride	89	36
Wixela Inhub	Fluticasone Propion/Salmeterol	88	28
Fluoxetine Hcl	Fluoxetine Hcl	76	30
Bupropion Xl	Bupropion Hcl	75	24
Hydralazine Hcl	Hydralazine Hcl	75	28
Jardiance	Empagliflozin	74	23
Trospium Chloride	Trospium Chloride	73	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	72	25
Clobetasol Propionate	Clobetasol Propionate	70	38
Montelukast Sodium	Montelukast Sodium	66	23
Tizanidine Hcl	Tizanidine Hcl	65	22
Prednisone	Prednisone	64	50
Glipizide	Glipizide	60	19
Citalopram Hbr	Citalopram Hydrobromide	59	21
Clopidogrel	Clopidogrel Bisulfate	59	18
Triamcinolone Acetonide	Triamcinolone Acetonide	58	35
Ciprofloxacin Hcl	Ciprofloxacin Hcl	57	46
Metformin Hcl	Metformin Hcl	56	20
Lovastatin	Lovastatin	55	17
Allopurinol	Allopurinol	54	19
Meloxicam	Meloxicam	54	18
Rosuvastatin Calcium	Rosuvastatin Calcium	53	18
Escitalopram Oxalate	Escitalopram Oxalate	50	16
Lorazepam	Lorazepam	49	25
Estradiol	Estradiol	48	19
Zolpidem Tartrate	Zolpidem Tartrate	48	11
Acyclovir	Acyclovir	47	23
Pravastatin Sodium	Pravastatin Sodium	47	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	45	16
Spiriva Respimat	Tiotropium Bromide	44	12
Tramadol Hcl	Tramadol Hcl	43	12
Carvedilol	Carvedilol	42	12
Cephalexin	Cephalexin	40	33
Quetiapine Fumarate	Quetiapine Fumarate	38	12
Sumatriptan Succinate	Sumatriptan Succinate	38	12
Pradaxa	Dabigatran Etexilate Mesylate	37	17
Spironolactone	Spironolactone	37	13
Donepezil Hcl	Donepezil Hcl	36	11
Warfarin Sodium	Warfarin Sodium	36	15
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	35	15
Alprazolam	Alprazolam	34	12
Pioglitazone Hcl	Pioglitazone Hcl	34	13
Propranolol Hcl	Propranolol Hcl	33	11
Fluocinonide	Fluocinonide	31	22
Ondansetron Hcl	Ondansetron Hcl	31	19
Venlafaxine Hcl Er	Venlafaxine Hcl	31	suppressed
Naproxen	Naproxen	29	15
Glimepiride	Glimepiride	28	12
Clonazepam	Clonazepam	27	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	27	suppressed
Azithromycin	Azithromycin	26	24
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	25	suppressed
Humulin N	Insulin Nph Human Isophane	24	suppressed
Temazepam	Temazepam	24	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Metronidazole	Metronidazole	22	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	22	18
Digoxin	Digoxin	21	suppressed
Hydrocortisone	Hydrocortisone	21	15
Azelastine Hcl	Azelastine Hcl	20	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Humalog Kwikpen U-100	Insulin Lispro	20	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	20	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Carbamazepine	Carbamazepine	18	suppressed
Finasteride	Finasteride	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	11
Ozempic	Semaglutide	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Breyna	Budesonide/Formoterol Fumarate	17	suppressed
Colchicine	Colchicine	17	suppressed
Eliquis	Apixaban	17	suppressed
Propranolol Hcl Er	Propranolol Hcl	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Baclofen	Baclofen	15	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	12
Retin-A	Tretinoin	15	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Cartia Xt	Diltiazem Hcl	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Doxycycline Monohydrate	Doxycycline Monohydrate	12	suppressed
Humulin R	Insulin Regular, Human	12	suppressed
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error